Global Macular Degeneration Treatment Market Report 2022: Rising Burden of Retinal Disorders to Support Industry Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The Report “Global Market Report of Macular Degeneration Treatment Market 2022” has been added to from ResearchAndMarkets.com offer.

The global macular degeneration treatment market is expected to grow from USD 7.55 billion in 2021 to USD 8.08 billion in 2022 at a compound annual growth rate (CAGR) of 7.04%. The market is expected to reach $10.65 billion in 2026 with a CAGR of 7.15%.

In 2021, North America will be the largest region in the macular degeneration treatment market. Asia-Pacific is expected to be the fastest growing region during the forecast period. Regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The growing burden of retinal disorders is expected to propel the growth of the macular degeneration treatment market. Retinal disorders affect vital tissues and affect how individuals process visual information, resulting in distorted or absent vision. According to a 2020 study in Tanzania on the prevalence of retinal diseases and associated risk factors, out of 1,007 people, the prevalence of vitreoretinal disorders was 22.8% (230/1,007).

The study was conducted by OSLI Retina, which focuses solely on retinal diseases, surgery and drug therapy. The main retinal diseases were age-related hypertensive macular scarring (2.7%), retinopathy (4.5%) and degeneration (7.0%). According to the American Academy of Opthalmology, by 2050 an estimated 7.32 million people in the United States will have primary open-angle glaucoma, with the highest number among populations aged 70-79 (32%) , women (50%), and Hispanics (50%). The largest demographic group is Hispanic men. Hence, the growing burden of retinal disorders is driving the growth of the macular degeneration treatment market.

The development of advanced therapies is a key trend that is gaining popularity in the macular degeneration treatment market. Advanced therapy, including gene therapy, for the treatment of disease has developed in recent years, particularly in the world of inherited retinal diseases.

For example, in 2019, Spark Therapeutics, a US-based gene therapy treatment company, developed Luxturna, a therapy designed to treat patients with mutations in a gene called RPE65, which encodes a retinal protein necessary for eye to respond to light.

In September 2021, Novartis, a Swiss-based pharmaceutical company, acquired Arctos Medical for an undisclosed amount. The acquisition should enable Novartis to find treatments for patients with vision loss and exploit the potential of optogenetics as the basis for effective therapies. Arctos Medical is a Swiss developer of smart medical devices and gene therapy approaches for ophthalmological diseases for the treatment of blindness.

The countries covered in the Macular Degeneration Treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea South, the United Kingdom and the United States.

Scope

Covered markets:1) By disease stage: early-stage AMD; intermediate AMD; advanced AMD

2) By end user: ambulatory surgery centers; eye clinics; Hospitals

3) By route of administration: oral; injectables; Others

4) By types: wet macular degeneration, dry macular degeneration

Main topics covered:

1. Summary

2. Characteristics of the Macular Degeneration Treatment Market

3. Macular Degeneration Treatment Market Trends and Strategies

4. Impact of COVID-19 on the treatment of macular degeneration

5. Macular Degeneration Treatment Market Size and Growth

6. Macular Degeneration Treatment Market Segmentation

7. Regional and Country Analysis of Macular Degeneration Treatment Market

8. Asia-Pacific Macular Degeneration Treatment Market

9. Chinese Macular Degeneration Treatment Market

10. Macular Degeneration Treatment Market in India

11. Japan Macular Degeneration Treatment Market

12. Australia Macular Degeneration Treatment Market

13. Indonesia Macular Degeneration Treatment Market

14. South Korea Macular Degeneration Treatment Market

15. Western Europe Macular Degeneration Treatment Market

16. UK Macular Degeneration Treatment Market

17. Germany Macular Degeneration Treatment Market

18. France Macular Degeneration Treatment Market

19. Eastern Europe Macular Degeneration Treatment Market

20. Russia Macular Degeneration Treatment Market

21. North America Macular Degeneration Treatment Market

22. US Macular Degeneration Treatment Market

23. South America Macular Degeneration Treatment Market

24. Brazil Macular Degeneration Treatment Market

25. Middle East Macular Degeneration Treatment Market

26. Africa Macular Degeneration Treatment Market

27. Macular Degeneration Treatment Market Competitive Landscape and Company Profiles

28. Key mergers and acquisitions in the macular degeneration treatment market

29. Macular Degeneration Treatment Market Future Outlook and Potential Analysis

30. Appendix

Companies cited

  • Novartis AG

  • Bausch Health Companies Inc.

  • Regenxbio inc.

  • F Hoffmann-La Roche Ltd

  • Regeneron Pharmaceuticals Inc.

  • GlaxoSmithKline plc

  • Bayer AG

  • Neurotech Pharmaceutical Inc.

  • Ophthalmology company

  • Stem Cells Inc.

  • Pfizer Inc.

  • Santen Pharmaceuticals

  • Alimera Sciences Inc.

  • Aerie Pharmaceutical Inc.

  • Panopticon

  • Allergan Inc.

  • Valiant Pharmaceuticals

  • Rxi Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/r/6cqav8

Comments are closed.